Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TIVO-3 trial (tivozanib): what clinicians have said so far
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
- NCT02627963 ↗
- Completed
- AVEO Pharmaceuticals, Inc.
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on TIVO-3 (tivozanib in relapsed/refractory advanced renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TIVO-3 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 37 posts on X | |
| 23 YouTube videos | |
| 21 podcast episodes | |
| 1 video on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Tivozanib hydrochloride; Sorafenib
- Arms
- Tivozanib hydrochloride · Experimental
- Sorafenib · Active comparator
- Enrollment
- 350
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor
- AVEO Pharmaceuticals, Inc.
- Start
- May 24, 2016
- Primary completion
- Oct 4, 2018
- Results posted
- Yes
- Registry record
- NCT02627963 · updated Jul 18, 2023
Publications
linked from the registry- Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, Verzoni E. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. Oncologist. 2024 Mar 4;29(3):254-262. doi: 10.1093/oncolo/oyad348. PubMed 38262444
- Meza L, McDermott DF, Escudier B, Hutson TE, Porta C, Verzoni E, Atkins MB, Kasturi V, Pal SK, Rini B. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. Oncologist. 2023 Mar 17;28(3):e167-e170. doi: 10.1093/oncolo/oyac255. PubMed 36576430
- Szarek M, Needle MN, Rini BI, Pal SK, McDermott DF, Atkins MB, Hutson TE, Escudier BJ. Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Clin Genitourin Cancer. 2021 Oct;19(5):468.e1-468.e5. doi: 10.1016/j.clgc.2021.03.018. Epub 2021 Apr 3. PubMed 33980467
- Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, Verzoni E, Needle MN, McDermott DF. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020 Jan;21(1):95-104. doi: 10.1016/S1470-2045(19)30735-1. Epub 2019 Dec 3. PubMed 31810797